Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
More people are addicted to marijuana, but fewer of them are seeking help, experts say - 2Treasure trove found in Egyptian tomb solves ancient mystery
- 3'Tangled' live-action movie casts Teagan Croft and Milo Manheim as Rapunzel and Flynn
- 4How did this 20-light-year-wide 'Diamond Ring' form in space? Maybe a cosmic bubble burst
- 5Instructions to Pick the Right Toothpaste for Your Dental Requirements
- NASA Artemis II tracker: Crew less than 60,000 miles from moon ahead of Monday flyby
- Avoid Large Crowds In Bali & Swim At This Peaceful Waterfall With A Gorgeous, Natural Pool
- Egypt seeks to calm tourist fears over fallout of Iran war
- 10 Demonstrated Tips to Dominate Video Altering on Your Cell phone in 2023
- Game theory explains why reasonable parents make vaccine choices that fuel outbreaks
- Blue Origin safely launches wheelchair user to space and back
- Mummified cheetahs found in Saudi caves shed light on lost populations
- My Enterprising Excursion: Building a Startup
- Meet Beef the bulldog, who takes slow walks with his 78-year-old friend
